Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer

References

• Timmers L, Beckeringh JJ, van Herk-Sukel MP, Boven E, Hugtenburg JG. Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008 Pharmacoepidemiol Drug Saf.
   Google Scholar
• Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for all oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;1:110–115. doi:10.1200/JCO.1997.15.1.110
   Web of Science ®Google Scholar
• Regnier Denois V, Poirson J, Nourissat A, Jacquin JP, Guastalla JP, Chauvin F. Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists. Eur J Cancer Care (Engl). 2011;4:520–527. doi:10.1111/j.1365-2354.2010.01212.x
   Web of Science ®Google Scholar
• DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40:794–811. doi:10.1097/00005650-200209000-0000912218770
   PubMed Web of Science ®Google Scholar
• Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15. doi:10.1136/bmj.38875.675486.5516790458
   PubMed Web of Science ®Google Scholar
• Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56–66. doi:10.3322/caac.2000419147869
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381–2388. doi:10.1200/JCO.2009.26.308720385986
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Adherence to Long-Term Therapies: Evidence for Action. Geneva: WHO; 2003.
   Google Scholar
• Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245–255. doi:10.1002/ijc.2586421170960
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–312. doi:10.1016/S0140-6736(12)61900-X23177514
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619–629. doi:10.1016/S1470-2045(15)70156-725981818
   PubMed Web of Science ®Google Scholar
• Del Prete S, Cennamo G, Leo L, et al. Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study. Future Oncol. 2017;5:415–423. doi:10.2217/fon-2016-0421
   Web of Science ®Google Scholar
• Barillet M, Prevost V, Joly F, Clarisse B. Oral antineoplastic agents: how do we care about adherence? Br J Clin Pharmacol. 2015;80:1289–1302. doi:10.1111/bcp.1273426255807
   PubMed Web of Science ®Google Scholar
• Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol. 1990;8:1935–1937. doi:10.1200/JCO.1990.8.12.19352230885
   PubMed Web of Science ®Google Scholar
• Sugita K, Kawakami K, Yokokawa T, et al. Self-reported adherence to trifluridine and tipiracil hydrochloride for metastatic colorectal cancer: a retrospective cohort study. Oncology. 2016;91:224–230. doi:10.1159/00044871727513940
   PubMed Web of Science ®Google Scholar
• Nonomiya Y, Yokokawa T, Kawakami K, et al. Regorafenib-induced hand-foot skin reaction is more severe on the feet than on the hands. Oncol Res. 2019;27:551–556. doi:10.3727/096504018X1529172758974029914591
   PubMed Web of Science ®Google Scholar
• Yoon SE, Lee SJ, Lee J, et al. The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice. Onco Targets Ther. 2018;12:225–231. doi:10.2147/OTT.S18762130636885
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Komatsu Y, Satoh T, et al. Large-Scale, Prospective Observational Study of Regorafenib in Japanese patients with metastatic colorectal cancer in a real-world clinical setting. Oncologist. 2019;24:e450–e457. doi:10.1634/theoncologist.2018-037730606885
   PubMed Web of Science ®Google Scholar
• Yoshino T, Komatsu Y, Yamada Y, et al. Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Invest New Drugs. 2015;33:740–750. doi:10.1007/s10637-014-0154-x25213161
   PubMed Web of Science ®Google Scholar
• Perreault S, Blais L, Lamarre D, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol. 2005;59:564–573. doi:10.1111/j.1365-2125.2005.02355.x15842555
   PubMed Web of Science ®Google Scholar
• Yang -C-C, Jick SS, Testa MA. Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics. Br J Clin Pharmacol. 2003;56:84–91. doi:10.1046/j.1365-2125.2003.01818.x12848779
   PubMed Web of Science ®Google Scholar
• Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukemia. Pharmacoeconomics. 2007;25:481–496. doi:10.2165/00019053-200725060-0000417523753
   PubMed Web of Science ®Google Scholar
• Kimura M, Nakashima K, Usami E, et al. Adherence and awareness of the therapeutic intent of oral anticancer agents in an outpatient setting. Oncol Lett. 2015;9:2341–2346. doi:10.3892/ol.2015.302726137068
   PubMed Web of Science ®Google Scholar
• Timmers L, Boons CC, Kropff F, et al. Adherence and patients experiences with the use of oral anticancer agents. Acta Oncol. 2014;53:259–267. doi:10.3109/0284186X.2013.84435324266637
   PubMed Web of Science ®Google Scholar
• Burkiewicz JS, Fit KE. Improving adherence–sharing experiences. Ann Pharmacother. 2007;12:2058–2060. doi:10.1345/aph.1K350
   Web of Science ®Google Scholar
• Mathes T, Pieper D, Antoine SL, Eikermann M. Adherence influencing factors in patients taking oral anticancer agents: a systematic review. Cancer Epidemiol. 2014;38:214–226. doi:10.1016/j.canep.2014.03.01224768601
   PubMed Web of Science ®Google Scholar
• McCue DA, Lohr LK, Pick AM. Improving adherence to oral cancer therapy in clinical practice. Pharmacotherapy. 2014;34:481–494. doi:10.1002/phar.139924877187
   PubMed Web of Science ®Google Scholar